Frontiers in Oncology (Jan 2023)

Contribution of natural killer cells in innate immunity against colorectal cancer

  • Zeinab Ghazvinian,
  • Shahrokh Abdolahi,
  • Samaneh Tokhanbigli,
  • Shadi Tarzemani,
  • Andrea Piccin,
  • Andrea Piccin,
  • Andrea Piccin,
  • Mohammad Reza Zali,
  • Javad Verdi,
  • Kaveh Baghaei

DOI
https://doi.org/10.3389/fonc.2022.1077053
Journal volume & issue
Vol. 12

Abstract

Read online

Natural killer cells are members of the innate immune system and promote cytotoxic activity against tumor or infected cells independently from MHC recognition. NK cells are modulated by the expression of activator/inhibitory receptors. The ratio of this activator/inhibitory receptors is responsible for the cytotoxic activity of NK cells toward the target cells. Owing to the potent anti-tumor properties of NK cells, they are considered as interesting approach in tumor treatment. Colorectal cancer (CRC) is the second most common cause of death in the world and the incidence is about 2 million new cases per year. Metastatic CRC is accompanied by a poor prognosis with less than three years of overall survival. Chemotherapy and surgery are the most adopted treatments. Besides, targeted therapy and immune checkpoint blockade are novel approach to CRC treatment. In these patients, circulating NK cells are a prognostic marker. The main target of CRC immune cell therapy is to improve the tumor cell’s recognition and elimination by immune cells. Adaptive NK cell therapy is the milestone to achieve the purpose. Allogeneic NK cell therapy has been widely investigated within clinical trials. In this review, we focus on the NK related approaches including CAR NK cells, cell-based vaccines, monoclonal antibodies and immunomodulatory drugs against CRC tumoral cells.

Keywords